Nasdaq · Healthcare
Maze Therapeutics, Inc. (MAZE)
As-reported financials and recent SEC filings for Maze Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
—
Net income
$-131.1M
Net margin
—
Diluted EPS
$-3.05
ROE
-36.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2025 |
|---|---|---|
| Revenue | — | $167.5M |
| Gross profit | — | — |
| Operating income | $-142.9M | $57.6M |
| Net income | $-131.1M | $52.2M |
| Diluted EPS | $-3.05 | $0.08 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-01
View on EDGAR →1442026-07-01
View on EDGAR →1442026-07-01
View on EDGAR →42026-06-24
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →Largest Healthcare peers
Go deeper on MAZE
Search Maze Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.